The read at a glance
Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -44.27 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.69 — flag raised, worth a closer lookWatch
- Earnings quality 68/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2026, as Sonoma Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Human Care$17.7M
- Animal Care$1.8M
Leadership changes
From Sonoma Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Vanessa Jacoby · director · appointmenteff. 2026-01-28
- Jay Birnbaum · Directors · departureeff. 2026-01-28
- Bruce Thornton · Chief Operating Officer · departureeff. 2025-12-02
Latest filings
- 8-K · Company announcement2026-06-18
- 10-K · Annual report2026-06-16
- DEF 14A · Annual proxy (pay & governance)2026-05-05
- 8-K · Company announcement2026-04-30
- 8-K · Company announcement2026-04-09
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Sonoma Pharmaceuticals, Inc., every answer cited🔒
- The Intelligence Brief — added when Sonoma Pharmaceuticals, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.